User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4193

Interactions with Platform & by Email *

INTERACTIONS

755

Unique # Participated *

PARTICIPANTS

126

Responses Validated *

VALIDATIONS

36

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Current & Future Analysis.....II-1
High Unmet Need and Challenges Abound, But Hope Persists.....II-1
A Difficult to Diagnose and Treat Cancer.....II-1
1$100
   At Odds with Life After Pancreatic Cancer.....II-2
Combination Therapies A Potential Contender for Treatment.....II-2
Clinical Research In Search of Breakthrough Therapy.....II-2
Active Pancreatic Cancer Pipeline A Ray of Hope!.....II-2
1$100
   Targeted Therapy The Promise, The Potential!.....II-31$100
   Research and Development A Tough, Uphill Journey.....II-4
Clinical Trials Failure Flickers The Hope for Pancreatic Cancer Treatment.....II-4
Gemcitabine Fixation Mars Pancreatic Cancer Research.....II-4
Competitive Landscape.....II-4
1$100
   Select Approved Drugs for Metastatic Pancreatic Cancer.....II-5
United States - A Regional Overview.....II-5
Pancreatic Cancer - Incidence and Mortality.....II-5
Table 1: The American Cancer Societys 5-year Relative Survival Rate for Patients with Pancreatic Cancer by Disease Stage (includes corresponding Graph/Chart).....II-5
1$350
   Poor Prognosis, Late Diagnosis and High Unmet Needs The Challenges.....II-6
The Funding Face Off.....II-6
United Kingdom - A Regional Overview.....II-6
Pancreatic Cancer Brits Patients Fighting for Survival.....II-6
1$100
   Pancreas The Vital Body Organ.....II-7
Pancreatic Cancer The Devastating Disease.....II-7
Risk Factors of the Disease.....II-7
1$100
   Prevention of the Disease.....II-8
Symptoms of the Disease.....II-8
Diagnosis of the Disease.....II-8
1$100
   Abdominal Ultrasound.....II-9
CT Scan.....II-9
Percutaneous Biopsy.....II-9
Endoscopic Biopsy.....II-9
Treatment of the Disease.....II-9
1$100
   Surgical Treatment.....II-10
Therapeutic Treatment.....II-10
Treatment with Chemotherapy Drugs.....II-10
1$100
   Gemcitabine (Gemzar).....II-11
Table 2: Gemzar Sales by Region: 2007 and 2008 (USD Million) (includes corresponding Graph/Chart).....II-11
Fluorouracil (5-FU).....II-11
1$350
   Capecitabine (Xeloda).....II-12
Treatment with Targeted Drug Therapy.....II-12
Erlotinib (Tarceva).....II-12
1$100
   Table 3: Tarceva Pancreatic Cancer Sales Worldwide: 2007-2012 (includes corresponding Graph/Chart).....II-13
Treatment with Radiation Therapy.....II-13
1$350
   Other Therapies.....II-141$100
   Pfizer Announces Encouraging Results of Sutent, Stops Trial Ahead of Schedule.....II-15
Abraxis BioScience Announces Interim Phase II Data for Abraxane.....II-15
Concordia Announces Phase I/II Trial Results of Pancreatic Cancer Drug.....II-15
1$100
   Infinity Pharma Announces Preclinical Data of IPI-926.....II-16
Celsion and Philips Complete Feasibility Stage, Commence Preclinical
  Development.....II-16
1$100
   Mayo Clinic Reports Encouraging Test Results of a New Drug Combination.....II-17
Sidney Kimmel Researchers Report Positive Tigatuzumab Plus Gemcitabine Results.....II-17
NCI Scientists Discover New Approach to Treat Pancreatic Cancer.....II-17
1$100
   Jefferson Researchers Report Potential of Herbal Extract in Pancreatic Cancer.....II-18
American and Indian Scientists Discover New Pancreatic Cancer Therapy.....II-18
1$100
   Cambridge Scientists Discover Cause of Drug Failure in Pancreatic Cancer.....II-19
CytRx Corp. Announces Trial Results of INNO-206.....II-19
1$100
   Amgens AMG 479 Shows Potential for Pancreatic Cancer Treatment.....II-20
BioCancell Receives FDA Approval for BC-819 Phase I/II Trials.....II-20
Rexahn Secures FDA Approval Phase II Trial of Archexin in Pancreatic Cancer.....II-20
1$100
   NeoPharm Files Application for Phase II Trial of LE-DT.....II-21
Regeneron and Sanofi-aventis Terminate Phase III Study of Aflibercept.....II-21
Pfizer Terminates Phase III Clinical Study of Axitinib.....II-21
SciClone Terminates Phase II Trial of Pancreatic Cancer Drug.....II-21
1$100
   MediGene Announces Final Results of Phase II EndoTAG-1 Study.....II-22
Abraxis BioScience Announces Positive Phase I Trial Results.....II-22
Immunomedics Announces Development of Novel Antibody-Drug Conjugates.....II-22
1$100
   Roches Study Shows Avastin Plus Tarceva to Benefit Pancreatic Cancer Patients.....II-23
Morphotek Inaugurates Additional Phase II Study Sites in EU.....II-23
Pharmexa Announces Disappointing Data on GV1001, Terminates Study.....II-23
Oncoscience to Commence New Phase IIb/IIIa Trial for Nimotuzumab.....II-23
1$100
   Bristol-Myers and ImClone Announce Disappointing Phase III Results of Erbitux.....II-241$100
   Roche Acquires Genentech.....II-25
Sanofi-aventis Signs Agreement to Take Over BiPar Sciences.....II-25
Cell Genesys and BioSante Complete Merger.....II-25
1$100
   Agennix and GPC Biotech Announce Merger.....II-26
YM BioSciences Plans Merger with Cytopia.....II-26
Myriad Acquires License to PALB2 Pancreatic Cancer Gene Patents.....II-26
1$100
   Seattle Genetics, Agensys Expand ADC Collaboration.....II-27
Clavis Pharma Announces Agreement with Clovis Oncology for Anti-cancer Drug.....II-27
GlobeImmune Enters into Strategic Global Oncology Alliance with Celgene.....II-27
1$100
   Rexahn and Teva Close Agreements for New Anti-cancer Agent, RX-3117.....II-28
Taiho Pharma Announces Termination of S-1 Agreement with Sanofi-aventis.....II-28
Cancer Advances to Raise Funds for Pancreatic Cancer Drug Trial.....II-28
1$100
   MacroChem Announces Virium Pharmaceuticals Acquisition.....II-29
DARA BioSciences and Point Therapeutics Merge.....II-29
GeneSense and Zor Sign Exclusive License Agreement for Virulizin.....II-29
1$100
   Cobra and ViroMed Ink Agreement for Anti-cancer Drug Development.....II-30
GenVec and Cobra Ink Manufacturing Agreement.....II-30
ARIUS Research and Laureate Pharma Ink Agreement for Trop-2.....II-30
1$100
   Chugai Submits Application for Additional Indication of Pancreatic Cancer.....II-31
MediGene Secures FDAs Orphan Drug Designation for Anti-cancer Candidate.....II-31
Antisense Announces FDA and EMEA Orphan Drug Designation for Trabedersen.....II-31
1$100
   Clavis Announces EMEAs Orphan Drug Recommendation for CP-4126.....II-32
Epeius Receives FDAs Fast Track Designation for Rexin-G.....II-32
Abraxis BioScience Receives FDAs Orphan Drug Status for Abraxane.....II-32
Immunomedics Announces Fast Track Designation of FDA for hPAM4.....II-32
1$100
   Oncotherapy Science Plans Filing for Approval of Pancreatic Cancer Vaccine.....II-33
GenVec Announces FDAs Fast Track Designation for TNFerade.....II-33
PharmaEngine Receives FDAs Approval for PEP02 IND Application.....II-33
1$100
   Reata Receives FDAs Orphan Drug Status for Anti-cancer drug, RTA 402.....II-34
Marshall Edwards Announces FDA Orphan Drug Designation for Triphendiol.....II-34
Tau Receive FDAs Orphan Drug Status for Pancreatic Cancer Treatment.....II-34
Regulon Receives Orphan Designation for Pancreatic Cancer Candidate, Cisplatin.....II-34
Roche Wins European Approval for Tarceva.....II-34
2$125
   Abraxis BioScience, Inc. (USA).....II-36
Amgen, Inc. (USA).....II-36
Eli Lilly and Company (USA).....II-36
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-37
Genentech Inc. (USA).....II-37
1$100
   OSI Pharmaceuticals, Inc. (USA).....II-381$100
   Table 4: World Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-391$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com